skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pegylated liposomal doxorubicin in the management of ovarian cancer

Review

(1894) Views  (664) Full article downloads

Authors: Gabriella Ferrandina, Giacomo Corrado, Angelo Licameli, et al

Published Date September 2010 Volume 2010:6 Pages 463 - 483
DOI: http://dx.doi.org/10.2147/TCRM.S3348

Gabriella Ferrandina1,2, Giacomo Corrado1, Angelo Licameli1, Domenica Lorusso2, Gilda Fuoco1, Salvatore Pisconti3, Giovanni Scambia2
1Gynecologic Oncology Unit, Department of Oncology, Catholic University of Campobasso, Campobasso, Italy; 2Gynecologic Oncology Unit, Catholic University of Rome, Rome, Italy; 3Salvatore Pisconti, Oncology Unit, Taranto Hospital, Taranto, Italy

Abstract: Among the pharmaceutical options available for treatment of ovarian cancer, much attention has been progressively focused on pegylated liposomal doxorubicin (PLD), whose unique formulation, which entraps conventional doxorubicin in a bilayer lipidic sphere ­surrounded by a polyethylene glycol layer, prolongs the persistence of the drug in the ­circulation and potentiates intratumor drug accumulation. These properties enable this drug to sustain its very favorable toxicity profile and to be used safely in combination with other drugs. PLD has been already approved for treatment of advanced ovarian cancer patients failing first-line platinum-based treatment. Moreover, phase III trials have been already completed, and results are eagerly awaited, which hopefully will expand the range of PLD clinical application in this neoplasia both in front-line treatment, and in the salvage setting in combination with other drugs. Moreover, attempts are continuing to enable this drug to be combined with novel cytotoxic drugs and target-based agents. This review aims at summarizing the available evidence and the new perspectives for the clinical role of PLD in the management of patients with epithelial ovarian cancer.

Keywords: pegylated liposomal doxorubicin, ovarian cancer, clinical trials






Readers of this article also read:

Molecular markers of susceptibility to ocular toxoplasmosis, host and guest behaving badly
A review and empirical study of the composite scales of the Das–Naglieri cognitive assessment system
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Pegylated liposomal doxorubicin in ovarian cancer
Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis
Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program
Editorial
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Primary care for diabetes mellitus: perspective from older patients